Peritoneal metastases represent a site and stage of cancer that causes more severe suffering than any other, and it is an extremely common problem. In one large study, 8% of colon cancer patients presented with peritoneal metastases, and an additional 5% experienced peritoneal metastases after curative resection.
established the field of peritoneal surgery, and hundreds of surgeons have followed in his footsteps. His confident, emphatic approach has sparked a wave of international focus and research that has cemented the field and affected the lives of thousands of patients. Nevertheless, as with many surgical innovations, the practice has evolved faster than the data to support it, leaving many skeptics and critics.
The most common surgical treatment applied to peritoneal metastases from gastrointestinal primaries is cytoreductive surgery (CRS) and HIPEC. The CRS procedure is an important technique that for advanced tumors requires skill, experience, aptitude, and fortitude. The peritoneal surgeon must navigate throughout an adhesion-filled abdominal cavity and be prepared to comfortably perform everything from a pelvic peritonectomy with en bloc hysterectomy and proctectomy to careful resection of cemented tumor under the suprahepatic vena cava to distal pancreatectomy, gastrectomy, duodenal resection, ureteral stripping, periportal dissection, caudate resection, and more, often all in a single case. It requires a team of physicians, nurses, and ancillary staff dedicated to safe outcomes and minimal discomfort including personnel from the outpatient clinic, the operating room, the intensive care unit, the hospital floors, rehabilitation units, pain services, and palliative care teams. With this universal support, it still is a challenging procedure. Patients undergo 12-h operations with a 3.5% chance of dying before recovery from the operation and needing 6 months to return to a good quality of life. 5 The HIPEC treatment started with a description of the perfusion system in a canine model in 1980 6 and a case report from the same authors at the University of Louisville. 7 Next, a series of reports from Japan concerning gastric cancer were published, including randomized trials. [8] [9] [10] In the early 1990s, the French groups began reporting outcomes, 11 and articles from Sugarbaker's team 12 and Loggie et al., 13 as well as prospective clinical trials from Alexander and Fraker 14, 15 emerged from the United States. The first randomized trial for something other than gastric cancer was reported by Verwaal et al. 16 from the Netherlands, who reported on colon cancer in 2003. This trial demonstrated a remarkable survival advantage for CRS and HIPEC, but the control arm of the study used systemic 5-fluorouracil (5-FU) alone, an ineffective agent.
By 2005, more than 200 articles on the use of HIPEC were published, with a paucity of level 1 data. This flood of reports pushed the field forward in the absence of definitive clinical trials. Also problematic, the techniques varied greatly from 30 min of mild hyperthermia and oxaliplatin to 2 h of mitomycin C and severe hyperthermia, with everything in between. Sound pharmacokinetic analysis, an understanding of drug sensitivity, and the in vitro requirements for hyperthermia often were ignored or unavailable. To date, more than 1500 articles have been published on HIPEC, and more than 500 institutions across the world are performing CRS and HIPEC as the standard of care for peritoneal metastases, with many of the same limitations.
This educational review aims to update the readers on the most current recommendations for the management of peritoneal metastases from colorectal cancer, 17 mesothelioma, 18 and mucinous appendiceal neoplasms; 19 to describe the state of the art for cytoreductive surgery and HIPEC; 20 and to inform the readers on the important options for palliative management of peritoneal metastases. 21 We have solicited articles from thoughtful, highvolume experts in the field of peritoneal surgery so the reader can be confident that the existing data and recommendations are interpreted with a measure of personal experience and common sense.
In addition to understanding the existing data, it is essential to appreciate that many ongoing randomized trials across the world will continue to enlighten us about the role for HIPEC in the management of peritoneal metastases. A recent randomized trial of HIPEC in ovarian cancer was published in the New England Journal of Medicine, demonstrating a remarkable 13-month advantage in median overall survival for those patients receiving a 90-min HIPEC with cisplatin after cytoreduction compared with cytoreduction alone. 22 Although these results are consistent with those reported for gastrointestinal tumors and support the role of HIPEC for peritoneal metastases in general, it is also important to appreciate that the management of peritoneal metastases goes beyond HIPEC. It is incumbent on peritoneal surgeons to develop better treatments focused on the peritoneal cavity. For example, peritoneal metastases are uniquely accessible to biologic agents, such as oncolytic viruses which are ineffective when delivered systemically. 23 Intraperitoneal delivery of chimeric antigen receptor (CAR) T cells may be superior to systemic delivery. 24 The specialty of peritoneal surgery is here to stay. Peritoneal surgery is an important subspecialty within general surgical oncology, and peritoneal surgeons are going to be the drivers for advancements in the management of peritoneal metastases. It is a subspecialty that does not overlap with others and exists beyond the scope and interest of most general surgeons. As with almost all cancers, a multidisciplinary approach is essential, and tumor boards focused on peritoneal metastases will lead to the best outcomes. These unfortunate patients, who suffer with distention, pain, vomiting, profound weakness, and malnutrition, deserve special attention.
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